View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 11, 2017updated 13 Jul 2022 10:10am

Corium’s Corplex Donepezil demonstrates positive outcome in pilot BE trial

US-based Corium International has reported positive preliminary results from a pilot bioequivalence (BE) clinical trial of Corplex Donepezil in healthy subjects.

US-based Corium International has reported positive preliminary results from a pilot bioequivalence (BE) clinical trial of Corplex Donepezil in healthy subjects.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Corplex Donepezil is a once-weekly transdermal patch designed to deliver the prescribed treatment for all stages of Alzheimer’s disease.

The results showed that the product met the bioequivalence criteria that were examined using primary pharmacokinetic (PK) endpoints, when compared to oral Aricept (donepezil hydrochloride).

The six-month, randomised cross-over, three-period BE trial was conducted in 60 healthy male and female subjects.

The study compared the steady-state PK profiles of once-daily oral Aricept with 5mg of once-daily donepezil, followed by four weeks of 10mg once a day. 

"With this exciting clinical progress, we are finalising the scale up and related activities to support the start of our pivotal study this fall, with the objective of filing our new drug application (NDA) in 2018."

Corium chief technology officer and research and development vice-president Parminder Singh said: “We are extremely pleased that our Corplex Donepezil patches performed as well as we had projected, and that one of the tested patches actually met the regulatory bioequivalence criteria at the pilot stage. 

“Based on these results, we can now move forward knowing that we have a product candidate that can meet the bioequivalence-based registration criteria.

“With this exciting clinical progress, we are finalising the scale up and related activities to support the start of our pivotal study this fall, with the objective of filing our new drug application (NDA) in 2018.” 

Following the application of more than 500 patches, Corplex was found be well tolerated, and had favourable adhesion with positive skin safety and gastrointestinal side effect profiles.

The main objective of the trial was to establish parameters such as patch size for successful bioequivalence, while secondary objectives included evaluation of safety and tolerability.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena